Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4909-4916

  Salehi, Marzieh ^a   Vahl, Torsten P ^a   D'Alessio, David A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; EXENDIN [9 39]; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCOSE; INCRETIN; INSULIN; UNCLASSIFIED DRUG; XYLOSE;

ADULT; ARTICLE; CONTROLLED STUDY; EATING HABIT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INGESTION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIORITY JOURNAL; STOMACH EMPTYING; STOMACH MOTILITY;

EID: 57349122058     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0605     Document Type: Article

References (27)

1. Kieffer TJ, Habener JF 1999 The glucagon-like peptides. Endocr Rev 20:876-913
2. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498
3. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
4. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM 1998 Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:525-530
5. Prigeon RL, Quddusi S, Paty B, D'Alessio DA 2003 Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707
6. Ahren B, Schmitz O 2004 GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36:867-876
7. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
8. D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW 1996 Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138
9. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B 2006 Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251
10. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
11. Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R 1978 Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 62:152-161
12. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'Alessio DA 2006 β-Cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 91:185-191
13. Eberts TJ, Sample RH, Glick MR, Ellis GH 1979 A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol. Clin Chem 25:1440-1443
14. Tissot S, Normand S, Guilluy R, Pachiaudi C, Beylot M, Laville M, Cohen R, Mornex R, Riou JP 1990 Use of a new gas chromatograph isotope ratio mass spectrometer to trace exogenous 13C labelled glucose at a very low level of enrichment in man. Diabetologia 33:449-456
15. Bardet S, Pasqual C, Maugendre D, Remy JP, Charbonnel B, Sai P 1989 Inter and intra individual variability of acute insulin response during intravenous glucose tolerance tests. Diabete Metab 15:224-232
16. Vilsboll T, Krarup T, Madsbad S, Holst JJ 2003 Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121
17. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
18. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M 1998 Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-1430
19. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA 2007 Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 50:806-813
20. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH 2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
21. Medhus AW, Sandstad O, Bredesen J, Husebye E 2000 Stimulation of the small intestine by nutrients in relation to phase of the migrating motor complex. Scand J Gastroenterol 35:494-500
22. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ 1993 Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673
23. Nauck MA 1999 Is glucagon-like peptide 1 an incretin hormone? Diabetologia 42:373-379
24. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B 1996 Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103
25. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M 2002 Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.AmJ Physiol Gastrointest Liver Physiol 282:G424-G431
26. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M 2007 Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480
27. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723